+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Chronic Intracerebroventricular GABAergic Treatment on Basal and Chronic or Acute Stress-Induced Adrenocortical Activities in the Thalamic Pigeon

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Muscimol was chronically administrated to the third ventricle of thalamic pigeons by means of osmotic minipumps at the rate of 0.25 µg·h<sup>–1</sup> for 28 days. No abnormal behavioural sign was noted. The animals were subjected daily to chronic intermittent stress for the same 28-day period. Basal and stress-induced adrenocortical activities were evaluated by recording serial plasma corticosterone levels at the end of the experimental session. Untreated controls exhibited both components of the adaptation of the adrenocortical response to chronic stress: (1) attenuation, i.e., a decrease in magnitude and disappearance of the late rebounding phenomenon, and (2) anticipation, i.e., the occurrence of a conditioned component before stress itself. The adaptation to chronic stress was partly impaired by GABAergic treatment. The anticipatory conditioned peak subsisted but the magnitude of the post-stress peak was found not to be reduced whereas rebounding events were suppressed after chronic as well as acute stress. The basal resting levels of corticosterone were significantly lowered in muscimol-treated animals. A lesion placement in the anterior dorsomedial thalamus (ADMT) resulted in the same profile of stress-induced plasma corticosterone levels as seen after muscimol administration. Adaptation did not develop in ADMT animals and GABAergic stimulation, either acute or chronic, had no effect on their response to stress.

          Related collections

          Author and article information

          S. Karger AG
          01 April 2008
          : 44
          : 4
          : 408-414
          Laboratory of General Physiology, University Montpellier II, Montpellier, France
          124679 Neuroendocrinology 1986;44:408–414
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper


          Comment on this article